The Tsingke Gene Factory represents the core of Tsingke Biotech's vision — a fully integrated, intelligent platform for DNA/RNA synthesis that unites raw material production, instrument manufacturing, and advanced synthesis workflows under one roof. Our mission, Biotech for a Better World, drives us to empower scientific discovery and biopharmaceutical innovation worldwide.
With in-house reagents, self-developed synthesizers, and automation-driven manufacturing systems, the Tsingke Gene Factory is built for scale, speed, and precision — delivering from micrograms to industrial-scale production with uncompromising quality.
End-to-End Integration
Raw Material Production: DNA/RNA phosphoramidites, solid supports, and synthesis reagents produced in-house.
Instrument Development: Proprietary oligo synthesizers (12P, 192B, 768B), purifiers, and automation platforms.
Manufacturing Workflow: AI-driven production management system (Tsingke HelixTech) enabling real-time tracking, quality control, and lean manufacturing.
Synthesis Excellence
Gene Synthesis: Up to 200 kb in length with 160+ ready-to-use vectors, free codon optimization, and cloning services.
Oligo & Modified Nucleic Acids: Over 200 modification types, multiple purification options, and support for research, diagnostics, and therapeutics.
RNA Synthesis: mRNA, saRNA, circRNA with LNP formulation services.
Protein & Antibody Services: From gene to protein expression and purification.
Quality and Compliance
Facilities: 12,000 m² R&D center and 100,000-class cleanroom manufacturing space.
Certifications: ISO 9001, ISO 13485, and GMP-compliant production lines.
Validation: Full NGS verification, QC traceability, and strict SOP management.
From monomers to final product, all in-house for maximum quality control.
Streamlined workflows for faster turnaround and fewer errors.
From research-scale to industrial GMP batches.
Trusted by 300,000+ researchers worldwide.
Serving academia, diagnostics, and biotech companies across 100+ countries.
Founders began entrepreneurship in nucleic acid synthesis.
Founders began entrepreneurship in nucleic acid synthesis.
Entered chemical raw material production.
Entered chemical raw material production.
Expanded into gene detection services.
Expanded into gene detection services.
Launched oligonucleotide synthesis and modifications.
Launched oligonucleotide synthesis and modifications.
Developed self-owned synthesis instruments.
Developed self-owned synthesis instruments.
Began molecular reagent production.
Began molecular reagent production.
Founded Beijing Tsingke Biotechnology Co., Ltd.; launched gene synthesis business.
Founded Beijing Tsingke Biotechnology Co., Ltd.; launched gene synthesis business.
Completed Series A financing (RMB 150 million).
Completed Series A financing (RMB 150 million).
Completed Series B financing (RMB 400 million); launched nucleic acid drug platform
Completed Series B financing (RMB 400 million); launched nucleic acid drug platform
Corporate restructuring to Beijing Tsingke Biotechnology Co., Ltd. (Joint Stock).
Corporate restructuring to Beijing Tsingke Biotechnology Co., Ltd. (Joint Stock).
Stay updated with the latest industry news and expert insights.
Subscribe now to receive:
● Industry updates
● Exclusive expert insights and analysis
Enter your email to stay ahead!
